J. Safra Sarasin Holding AG Takes $699,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

J. Safra Sarasin Holding AG bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,453 shares of the company’s stock, valued at approximately $699,000.

Other large investors have also added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new position in Viridian Therapeutics in the 3rd quarter valued at about $8,917,000. JPMorgan Chase & Co. boosted its holdings in Viridian Therapeutics by 218.5% in the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after purchasing an additional 274,641 shares during the last quarter. Barclays PLC grew its stake in Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after purchasing an additional 66,550 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Viridian Therapeutics by 1,603.4% during the 3rd quarter. Principal Financial Group Inc. now owns 172,810 shares of the company’s stock worth $3,931,000 after purchasing an additional 162,665 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock valued at $596,000 after purchasing an additional 14,644 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Trading Down 1.6 %

NASDAQ VRDN opened at $13.54 on Thursday. The firm has a market capitalization of $1.10 billion, a PE ratio of -3.14 and a beta of 0.81. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20. The company has a 50-day simple moving average of $14.34 and a 200-day simple moving average of $18.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. On average, equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.